对固体瘤中SYK向的新见解
1Division of Pediatric Hematology-Oncology, Moores Cancer Center, University of California, San Diego, CA 92093-0815, USA.
Trends in pharmacological sciences
|September 25, 2024
概括
腺氨酸激酶 (SYK) 在固体瘤中起着双重作用,有时抑制,有时促进癌症. 向瘤微环境中的免疫细胞中的SYK提供了新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 腺氨酸激酶 (SYK) 主要存在于造血细胞中,在B细胞恶性瘤和自身免疫性疾病中发挥着既定的作用.
- 在上皮固体瘤中,SYK表现出一种矛盾的功能,在某些癌症中起到瘤抑制作用,在其他癌症中起到瘤生长促进作用.
- 新兴研究强调SYK在瘤微环境 (TME) 的参与,其在免疫细胞中的信号传递有助于免疫抑制和瘤进展.
研究的目的:
- 在固体瘤的背景下,审查腺氨酸激酶 (SYK) 的演变作用.
- 阐明癌症中SYK激活背后的机制.
- 总结关于用于固体瘤治疗的SYK抑制剂的临床前和临床发现.
主要方法:
- 在实体瘤中SYK临床前研究的文献综述.
- 对TME内的免疫细胞 (B细胞,髓状细胞) 中SYK信号通路的研究分析.
- 对单疗法和组合治疗中SYK抑制剂的临床试验数据的检查.
主要成果:
- 在TME内的免疫细胞中SYK信号促进免疫抑制,瘤生长,并在各种固体瘤中转移.
- 目前正在研究SYK抑制剂作为潜在的独立疗法或与免疫疗法和化疗结合使用.
- SYK (瘤抑制剂与促进剂) 的矛盾作用取决于特定的癌症类型和背景.
结论:
- 准免疫细胞中的SYK代表了对固体瘤的有希望的治疗途径.
- 需要进一步的研究,以充分理解SYK的复杂作用,并优化基于抑制剂的治疗策略.
- 涉及SYK抑制剂的组合疗法可能会提高固体瘤的治疗疗效.
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491


